Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, Metastatic Lung Cancer, Metastatic Prostate Cancer
Conditions
Keywords
Docetaxel, Alpha 1 Acid Glycoprotein, Outcome
Brief summary
Docetaxel based chemotherapy is a standard therapy in various metastatic cancers including lung cancer, breast cancer, gastric cancer, prostate cancer, and bladder cancer. One of the main plasma protein carriers of docetaxel is Alpha 1 acid glycoprotein. Retrospective data suggests that plasma level of alpha 1 acid glycoprotein is associated with the outcome of docetaxel based therapy in cancer patients. The investigators aim to prospectively study the association between the plasma level of alpha 1 acid glycoprotein and the outcome of docetaxel based therapy in cancer patients.
Detailed description
Docetaxel based chemotherapy is a standard therapy in various metastatic cancers including non small cell lung cancer, breast cancer, gastric cancer, prostate cancer, and bladder cancer. One of the main plasma protein carriers of docetaxel is Alpha 1 acid glycoprotein Retrospective data suggests that plasma level of alpha 1 acid glycoprotein is associated with the outcome of docetaxel based therapy in non small cell lung cancer patients. The investigators aim to prospectively study the association between the baseline plasma level of alpha 1 acid glycoprotein (measured on the first day of the first cycle of docetaxel) and the outcome (response rete, progression free survival, overall survival) of docetaxel based therapy in patients with metastatic non small cell lung cancer, breast cancer, stomach cancer, prostate cancer, and bladder cancer.
Interventions
None listed
Sponsors
Gottfried Maya
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patients with metastatic cancer from lung, breast, gastric, prostate, and bladder origin * patients must be treated with docetaxel based chemotherapy * patients must sign an informed consent form
Exclusion criteria
* patients with metastatic cancer other than lung, breast, gastric, prostate, and bladder origin * patients treated with chemotherapy other than docetaxel * patients that did not sign an informed consent form
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The association between the baseline plasma level of alpha 1 acid glycoprotein and progression free survival of docetaxel based therapy in patients with metastatic cancer | 3 years | The association between the baseline plasma level of alpha 1 acid glycoprotein and progression free survival of docetaxel based therapy in patients with metastatic non small cell lung cancer, breast cancer, gastric cancer, prostate cancer, and bladder cancer |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The association between the baseline plasma level of alpha 1 acid glycoprotein and the response rate and overall survival of docetaxel based therapy in patients with metastatic cancer | 3 years | The association between the baseline plasma level of alpha 1 acid glycoprotein and the response rate and overall survival of docetaxel based therapy in patients with metastatic non small cell lung cancer, breast cancer, gastric cancer, prostate cancer, and bladder cancer |
Countries
Israel
Contacts
Primary ContactDaniel Keizman, MD
Outcome results
None listed